Search Results - craig+thomas

10 Results

Sort By:

BODIPY-FL Nilotinib (Tasigna) for Use in Cancer Research

Abstract: The National Cancer Institute''s Laboratory of Cell Biology is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize bodipy conjugated tyrosine kinase inhibitors that are currently used in the clinic for the treatment of CML or gastric cancers. We are also...

Published: 7/25/2024 | Inventor(s): Suneet Shukla, Amanda Skoumbourdis, Craig Thomas, Suresh Ambudkar

Keywords(s): BODIPY-FL, nilotinib, Tasigna, Tyrosine Kinase Inhibitor (TKI)

Category(s): Application > Research Materials, Collaboration Sought > Licensing, TherapeuticArea > Oncology

Anti-Viral Compounds that Inhibit HIV Activity

Abstract: Several novel tropolone derivatives have been identified that inhibit HIV-1 RNase H function and have potential for anti-viral activity due to reduced cellular toxicity. Inhibiting RNase H function is a potential treatment for many viral infections, since RNase H function is essential for viral replication for many pathogenic retroviruses...

Published: 4/8/2024 | Inventor(s): John Beutler, Jian-kang Jiang, Suhman Chung, Craig Thomas, Stuart LeGrice, Jennifer Wilson

Keywords(s): AIDS, HIV, ribonuclease H, RNase H, tropolone derivative, viral replication

Category(s): Collaboration Sought > Licensing, Collaboration Sought > Collaboration, Application > Therapeutics, TherapeuticArea > Infectious Disease

Development and Use of O-linked beta-N-acetylglucosamine (O-GlcNAc) Transferase (OGT) Inhibitors for Multiple Conditions, Including Cancer

This technology includes the development and use of small molecules that inhibit O-linked beta-N-acetylglucosamine (O-GlcNAc) transferase (OGT) for a variety of pathologies, including Alzheimer's disease, cancer, cancer, diabetes, and neurodegenerative disorders the treatment of cancer and as a potential antiviral. OGT is a ubiquitous enzyme that catalyzes...

Published: 7/25/2024 | Inventor(s): Sara Martin Schwanger, Craig Thomas, Damien Duveau, Suzanne Walker

Keywords(s): 0-GlcNAc, Development, Developmtent, Inhibitors, OGT, THEREOF, TRANSFERASE, USES, VEXXXX, WIXXXX, WKXXXX

Category(s): Application > Research Materials, TherapeuticArea > Neurology, Application > Therapeutics

Treatment of Acute Myeloid Leukemia (AML) with the Multi-kinase FLT3-IRAK1/4 Inhibitor, NCGC1481, to Avoid Adaptive Resistance

This technology includes the identification and use of a novel small molecule, NCGC1481, to inhibit both the FLT3 and IRAK1/4 kinase pathways for treating acute myeloid leukemia (AML). An activating mutation of the FMS-like receptor kinase 3 (FMT3) occurs in approximately 25% of AML cases. Consequently, FLT3 inhibitors (FLT3i) have a good initial clinical...

Published: 7/25/2024 | Inventor(s): Jian-kang Jiang, Craig Thomas

Keywords(s): FTL3/IRAK, Inhibitors, MOLECULE, Small, VCXXXX, WIXXXX, WKXXXX, XEXXXX

Category(s): Application > Therapeutics, TherapeuticArea > Oncology, Application > Research Materials

Discovery of imidazo[1,2-b]pyridazines with Anticancer Properties

This technology includes a series of imidazo[1,2-b]pyridazines that display potent inhibition of FLT3, as well as potent binding and activity against FLT3 tyrosine kinase domain and gatekeeper mutations. This chemotype exhibits superior anti-leukemic activity against the common clinically-relevant FLT3-mutant acute myeloid leukemia (AML) in vitro and...

Published: 7/25/2024 | Inventor(s): Scott Hoyt, Patrick Sutter, Chris Finocchio, Daniel Starczynowski, Gregory Tawa, Craig Thomas

Keywords(s): 2-b]pyridazines, ANTICANCER, Discovery, Imidazo[1, PROPERTIES, VCXXXX, WIXXXX, WKXXXX

Category(s): Application > Therapeutics, Application > Research Materials, TherapeuticArea > Oncology

Use of the Ketamine Metabolite (R,6R)-hydroxynorketamine in Depression

This technology includes the identification and use of a ketamine metabolite, (2R,6R)-2-amino-2-(2-chlorophenyl)-6-hydroxycyclohexanone (HNK), for the treatment of depression. Ketamine is an NMDA receptor antagonist that exerts a rapid and sustained antidepressant and anti-suicidal effect. However, even low doses of ketamine has addictive and psychomimetic...

Published: 7/25/2024 | Inventor(s): Todd Gould, Irving Wainer, Carlos Zarate, Ruin Moaddel, Patrick Morris, Panos Zanos, Craig Thomas

Keywords(s): 2R, 6R-hydroxynorketamine, depression, Ketamine, METABOLITE, VEXXXX, VNXXXX, WIXXXX, WKXXXX

Category(s): TherapeuticArea > Neurology, TherapeuticArea > Psychiatry/Mental Health, Application > Therapeutics, Application > Research Materials

Pyruvate Kinase M2 Activators for the Treatment of Cancer

This technology describes a series of small-molecule activators of the pyruvate kinase M2 isoform (PK-M2). Pyruvate kinase (PK) is a critical metabolic enzyme that catalyzes the last step of the glycolytic pathway. It exists in several isoforms with different patterns of tissue expression. One isoform, PK-M2, is expressed in cells with a high rate...

Published: 7/25/2024 | Inventor(s): Jian-kang Jiang, Matthew Boxer, Min Shen, Douglas Auld, Craig Thomas

Keywords(s): Activator, ACTIVATORS, CANCER, CBXXXX, CXXXXX, Dimer, IBXXXX, ISOFORM, IXXXXX, M2, METABOLIC, METABOLITE, PK, PKM2, PK-M2, Proliferation, PYRUVATE, pyruvate kinase, small molecule, Tetramer, tumor

Category(s): Collaboration Sought > Collaboration, Application > Therapeutics, TherapeuticArea > Oncology, Application > Diagnostics, Application > Research Materials

Pyruvate Kinase M2 Activators for the Treatment of Cancer

NIH investigators have discovered a series of small compounds with the potential to treat a variety of cancers as well as hemolytic anemia. Contrary to most cancer medications, these molecules can be non-toxic to normal cells because they target a protein specific to the metabolic pathways in tumors, thus representing a significant clinical advantage...

Published: 7/25/2024 | Inventor(s): Min Shen, Craig Thomas, Douglas Auld, Matthew Boxer

Keywords(s): [1, [b], 2, 2-oxo-1, 3, 3-oxo-3, 4], 4-dihydroquinoline-2H-benzo, 4-tetrahydroquinoline-6-sulfonamides, ACTIVATORS, CB3CXX, CB3XXX, CBXXXX, CXXXXX, Human, Kinase, MOLECULE, Oxazine-7-sulfonamides, Patent Category - Chemistry, PYRUVATE, Small, Substituted

Category(s): Collaboration Sought > Collaboration, Application > Therapeutics, TherapeuticArea > Oncology

Caspase Inhibitors Useful for the Study of Autoimmune or Inflammatory Diseases

Novel and potent caspase 1 inhibitors are available for licensing. In particular, this technology discloses potent and selective caspase 1 inhibitors that target the active site of the enzyme. Caspase 1 is known to play a pro-inflammatory role in numerous autoimmune and inflammatory diseases and therefore represents an excellent target for treatment...

Published: 7/25/2024 | Inventor(s): Matthew Boxer, Craig Thomas

Keywords(s): 1, Amyotrophic lateral sclerosis, Amyotrophic lateral sclerosis 1; Amyotrophic lateral scleros, Amyotrophic lateral sclerosis 6, Caspase, IB3XXX, IBXXXX, Inflammatory bowel disease 1, inhibitor, IXXXXX, Lou Gehrig's disease, Patent Category - Chemistry

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Diagnostics, Application > Research Materials, Application > Therapeutics, TherapeuticArea > Immunology

Small Molecule Activators of Human Pyruvate Kinase for Treatment of Cancer and Enzyme-Deficient Hemolytic Anemia

Published: 7/25/2024 | Inventor(s): Craig Thomas

Keywords(s): 3-@hydroxyacyl-coa dehydrogenase deficiency, ACTIVATORS, CB3CXX, CB3XXX, CBXXXX, CXXXXX, HAD deficiency, HIS deficiency, Histidinemia, Human, Kinase, MOLECULE, Patent Category - Chemistry, PYRUVATE, Small

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Oncology